Predicting clinical response to anticancer drugs using 3D-bioprinted tumor models for personalized therapy

Project description

Recreating a patient's tumour ecoystem with 3D printing will foster precision treatment

One of the key problems with experimentation in model systems is the adequacy of the model system in representing the human disease or condition to be evaluated. In the case of cancer, it has become clear that the interaction of tumour cells with their microenvironment is critical to disease progression, metastasis and response to therapy. 3DCanPredict is developing a novel analytical system utilising a 3D bioprinted tumour model exploiting hydrogel scaffolds and a patient's own tumour cells. With functional blood vessels that can be infused with the patient's serum via a pump, not only does the system mimic the tumour microenvironment but it opens the door to personalised cancer medicine.

Fields of science

• medical and health sciences › clinical medicine › cancer

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)

Topic(s)

• ERC-2019-POC - ERC Proof of Concept Grant

Call for proposal

ERC-2019-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

TEL AVIV UNIVERSITY

Address

Ramat Aviv
69978 Tel Aviv
Israel

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 150 000

Beneficiaries (1)

TEL AVIV UNIVERSITY

Israel

EU contribution

€ 150 000

Address

Ramat Aviv
69978 Tel Aviv

Activity type

Higher or Secondary Education Establishments